1. Home
  2. CHH vs LEGN Comparison

CHH vs LEGN Comparison

Compare CHH & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Choice Hotels International Inc.

CHH

Choice Hotels International Inc.

N/A

Current Price

$98.39

Market Cap

5.0B

ML Signal

N/A

Logo Legend Biotech Corporation

LEGN

Legend Biotech Corporation

N/A

Current Price

$17.53

Market Cap

5.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CHH
LEGN
Founded
1939
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Hotels/Resorts
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.0B
5.9B
IPO Year
1997
2020

Fundamental Metrics

Financial Performance
Metric
CHH
LEGN
Price
$98.39
$17.53
Analyst Decision
Hold
Strong Buy
Analyst Count
11
12
Target Price
$114.30
$61.33
AVG Volume (30 Days)
441.6K
1.5M
Earning Date
04-30-2026
05-12-2026
Dividend Yield
0.98%
N/A
EPS Growth
27.42
N/A
EPS
1.84
N/A
Revenue
$1,596,793,000.00
N/A
Revenue This Year
$66.74
$42.68
Revenue Next Year
$0.37
$30.52
P/E Ratio
$53.39
N/A
Revenue Growth
0.75
N/A
52 Week Low
$84.04
$16.24
52 Week High
$123.82
$37.50

Technical Indicators

Market Signals
Indicator
CHH
LEGN
Relative Strength Index (RSI) 34.92 31.42
Support Level $93.51 $16.47
Resistance Level $98.71 $21.99
Average True Range (ATR) 3.14 0.88
MACD -0.64 -0.24
Stochastic Oscillator 10.83 3.31

Price Performance

Historical Comparison
CHH
LEGN

About CHH Choice Hotels International Inc.

At year-end 2025, Choice Hotels operated 657,000 rooms across the economy, midscale, upscale, and extended-stay segments. Comfort Inn and Comfort Suites are the largest brands (27% of the company's total rooms), while Ascend and Cambria (10%) are lifestyle and select-service brands, and WoodSpring (5%) is the company's largest extended-stay brand. Choice closed on its Radisson acquisition in August 2022, which added about 70,000 rooms. Franchises account for 100% of total revenue, and the United States represented 78% of total rooms in 2025.

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

Share on Social Networks: